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Objective. To identify the role of thrombolytic therapy in acute embolic stroke due to infective endocarditis. Design.C a s er e p o r t .
Setting. University hospital. Patient. A 70-year-old male presented with acute onset aphasia and hemiparesis due to infective
endocarditis. His head computerized tomographic scan revealed left parietal sulcal eﬀacement. He was given intravenous tissue
plasminogen activator with signiﬁcant resolution of the neurologic deﬁcits without complications. Main Outcome Measures.
Physicalexamination,NationalInstituteofHealthStrokeScale,radiologicexaminationresults. Conclusions. Thrombolytic therapy
in selected cases of stroke due to infective endocarditis manifesting as major neurologic deﬁcits can be considered as an option
after careful consideration of risks and beneﬁts. The basis for such favorable response rests in the presence of ﬁbrin as a major
constituent of the vegetation. The risk of precipitating hemorrhage with thrombolytic therapy especially with large infarcts and
mycotic aneurysms should be weighed against the beneﬁts of averting a major neurologic deﬁcit.
1.Introduction
The safety and eﬃcacy of thrombolytic treatment of acute
ischemic stroke due to septic brain embolism is not well
established [1]. Large trials of thrombolytic therapy of
acute ischemic stroke have excluded patients with septic
embolization. Published systematic reviews do not address
the role of the thrombolytic therapy in the setting of septic
embolization to the brain, such as in infective endocarditis
[2].
Stroke is the most common of neurologic complications
associated with infective endocarditis [3]. The treatment
and prevention strategies of this complication are still in
evolution. The prevention rests on initiating early antibiotic
therapy and consideration of surgery for recurrent events.
The role of thrombolytic therapy for acute ischemic strokes
in addition to antiplatelet therapy for the prevention of
recurrent strokes has increasingly been recognized. We
present here our experience of thrombolytic treatment of
acute ischemic stroke in a patient with unsuspected infective
endocarditis and the available evidence in the literature.
2.ClinicalSummary
A 70-year-old Caucasian male with history of hyperten-
sion and hyperlipidemia presented to a remote emergency
room with altered mental status, right hemiparesis, and
aphasia. On initial evaluation his National Institutes of
Health Stroke Scale (NIHSS) score was 13. A computed
tomographyscanoftheheadrevealedleftparietalhypodense
area without haemorrhage. Two and half-hour after the
onsetofsymptoms,intravenoustissueplasminogenactivator
(t-PA) was started at the outlying emergency room and
then transported to our University hospital for further
management. On presentation, patient had already ﬁnished
his t-PA infusion. On physical exam he had fever (39.7◦C)
and cardiac auscultation revealed a blowing 3/6-holosystolic
murmur at the apex. A transthoracic echocardiogram
revealed left ventricular ejection fraction of 60–65% with
moderate mitral regurgitation. Transesophageal echocardio-
gram revealed 1.6 × 1.2cm vegetation on the anterior mitral
valve leaﬂet (Figure 1). Blood cultures returned positive for
Streptococcus pneumoniae and he was started on penicillin2 Stroke Research and Treatment
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Figure 1: Transesophageal echocardiogram revealing vegetation on
the mitral valve leaﬂets.
Figure 2: Diﬀusion weighted MRI after thrombolysis showing
left parietal hyperintensities. Areas of focal intensities were also
identiﬁed in other location including the right cerebral hemisphere,
consistentwithembolicsourceasalikelycauseofthesebilateraland
sporadic hyperintense lesions.
G intravenous 5 × 106 units every four hours. A diﬀusion
weighted MRI of the brain (Figure 2) revealed bilateral acute
ischemic areas (left parietal and frontal regions in the left
middle cerebral artery distribution and in the right corona
radiata and right occipital lobe) and magnetic resonance
angiography was normal. Aspirin (81mg) was started one
day after thombolysis and penicillin G was continued for
6 weeks, followed by steady clinical improvement with
the continued care of physical, occupational, and speech
therapists. The NIHSS score was 5 at discharge with minimal
residual aphasia. Two months later, he was evaluated for
weight loss, anemia, and melena and was diagnosed with
carcinoma of the colon for which he successfully underwent
right hemicolectomy without any complication.
3. Discussion
The use thrombolytic therapy in patients with infective
endocarditis suﬀering from embolic events is not well
studied. Treatment with intravenous thrombolysis within 3
hours of symptom onset has become the standard of care in
acuteischemicstroke[4].Othertreatmentmodalitiessuchas
intra-arterial thrombo lysis and catheter-based mechanical
thrombus disruption therapies have been studied in the
treatment of acute ischemic stroke with variable success
[5–7]. The value and safety of these therapies in acute
stroke caused by embolism related to infective endocarditis
is evolving. Whether the increased risk of intracranial
hemorrhage in patients with infective endocarditis is to be
considered a contraindication for thrombolysis is unclear.
Mostofthesestrokesareischemicandthereforemayrespond
tothrombolysis.Ourcaseexamplealong withotherreported
cases of successful intravenous thrombolysis in patients
meeting the standard criteria for intravenous t-PA could
spur further studies to address this clinical scenario. Similar
reports of successful intra-arterial thrombolysis of basilar
artery and left internal carotid artery thrombosis in two
subjects with infective endocarditis need further evaluation
by well designed studies [1, 8]. We summarize the outcomes
of these four cases in Table 1.P u b l i c a t i o nb i a si sac o n c e r n
with such reports in the literature with only favourable
outcomes being reported.
Infective endocarditis is an endovascular microbial infec-
tion of cardiovascular structures, including large intratho-
racic vessels and intracardiac foreign bodies. The commonly
accepted pathogenetic theory is from endothelial injury with
deposition of noninfective sterile thrombotic vegetations to
transient bacteremia with microorganism adhesion (injury-
thrombus-infection theory). The characteristic lesions con-
sist of vegetations composed of platelets, ﬁbrin, micro-
organisms, and inﬂammatory cells [9]. Thus ﬁbrinolytic
therapy may be helpful in thrombus resolution by their
action on the ﬁbrin present in the vegetation itself or new
ﬁbrin that may develop after embolization. Local destructive
eﬀects, distant haematogenous seeding, immunologic and
embolic phenomena can complicate the clinical course of
infective endocarditis.
Embolism occurs in 20–40% of infective endocarditis
cases, but its incidence decreases to 9–21% after initiation
of antibiotic treatment. The risk of embolism is especially
high with large vegetations (>10mm), mobile vegetations
and during the early course of endocarditis therapy. The
brain and spleen are the most frequent sites of embolism in
infective endocarditis [10].
The overall incidence of stroke in patients with infective
endocarditis is about 10% and can result either from
embolic infarction or haemorrhage. Patients with mitral
valve endocarditis are at a greater risk of stroke than patients
with aortic valve endocarditis [3]. Cerebral embolism may
manifest as a stroke of varying severity associated with
fever, or may be asymptomatic [10]. In a retrospective
analysis by Hart et al. [11], 74% of ischemic strokes were
noted in native-valve endocarditis at presentation, 13%
occurred within 48 hours after diagnosis, and 9% of infarcts
are large. Hemorrhagic stroke in patients with infective
endocarditis occurs during the early stages (60% within 48
hours)ofclinicalcourseandthemechanismsresponsiblecan
be septic arteritis, secondary hemorrhagic transformation
of infarction, accompanying anticoagulation and mycotic
aneurysms [12]. Hemorrhagic conversion of the ischemic
infarct due to septic emboli is the most frequent mechanism
followed by the rupture of pyogenic arteritis and mycotic
aneurysms [13]. The presence of pathologic lesions such asStroke Research and Treatment 3
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pyogenic arteritis, mycotic aneurysms, and large infarcts due
to cerebral embolism increases the risk of hemorrhage with
thrombolytics in patients with infective endocarditis. The
relatively low incidence of 6% of intracranial hemorrhage
[11] and the factthat the ﬁbrin thrombus constitutes most of
the vegetation according to pathological studies [9] raise the
question whether infective endocarditis should be a relative
rather than an absolute contraindication in carefully selected
patients who may potentially beneﬁt from thrombolytic
therapy, in the absence of mycotic aneurysm and large
infarcts [8].
The cornerstone of medical treatment of infective
endocarditis is to institute eﬀective antibiotic therapy as
soon as possible to reduce the mortality and morbidity
from embolic complications and heart failure [10, 14].
The role of antiplatelet agents in the therapy of infective
endocarditis has been increasingly recognized. Anavekar et
al. [15] evaluated the eﬀects of preceding antiplatelet therapy
(aspirin, dipyridamole, clopidogrel, ticlopidine, or any of
combination) on the risk of embolism in a cohort of 600
cases of infective endocarditis. In this retrospective study,
embolic events occurred in 12.0% of patients who had
received prior antiplatelet therapy compared to 28% patients
who had not received therapy. This analysis demonstrates
that the risk of symptomatic emboli associated with infective
endocarditis is reduced in patients who received continuous
daily antiplatelet therapy before onset of infective endocardi-
tis.
Anticoagulation is still a matter of debate in infective
endocarditis, since it can increase the risk of complications,
mostly neurological. In a study of patients with native and
prosthetic valve endocarditis, stroke was signiﬁcantly more
frequent among anticoagulated patients (20% versus 7%)
than nonanticoagulated patients [16]. In a similar analysis,
patients who were already on anticoagulation for prosthetic
valves had the same embolic risk as compared to those
who are not on anticoagulation [14]. Oral anticoagulation
is ineﬀective in stroke prophylaxis, and their use may even
be associated with an increased case fatality rate, especially
for patients with Staphylococcus aureus infective endocarditis
[17]. Thus the indications for anticoagulation in infective
endocarditisremainsimilartothoseinvalvularheartdisease,
and anticoagulation with heparin should be maintained
whenever a brain infarct is present, unless it is large
and/or haemorrhagic [16]. European society of cardiology
guidelines recommend to discontinue coumadin therapy
and replace by heparin soon after the diagnosis of infective
endocarditis [18].
In spite of these positive outcomes in these selected case
reports, the mainstay of therapy of infective endocarditis
remains prompt antibiotic therapy. In all cases of acute
ischemic strokes, especially those with a history of fever,
infective endocarditis need to be considered and promptly
investigatedwithbloodculturesandechocardiographiceval-
uation. Whenever the clinical suspicion is high for infective
endocarditis, careful clinical judgement is required before
instituting thrombolytic therapy, weighing the beneﬁts of
averting a major neurologic deﬁcit with high NIHSS score
versus precipitating cerebral hemorrhage. Prior imaging to
identify the presence of mycotic aneurysm can be considered
whenever feasible to guide the decision to some extent,
however prior pathologic studies of infective endocarditis
attributed only a minority of cerebral hemorrhages to
the mycotic aneurysms [13]. Although current evidence is
lacking for the eﬀects of thrombolytic therapy on the clinical
course of mycotic aneurysms, it is intuitive to consider
increase the risk of cerebral hemorrhage with thrombolytic
therapy in the presence of mycotic aneurysm. Additionally
we believe publication bias in the literature on this subject is
a signiﬁcant issue with only favourable cases being reported.
In conclusion, thrombolytic therapy in cases of stroke
due to infective endocarditis manifesting with major neu-
rologic deﬁcits is a subject of controversy and needs careful
evaluation in a randomized trial. The beneﬁcial eﬀects of
therapy can be greatly jeopardised by the serious complica-
tions of intracranial hemorrhage.
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